Format

Send to

Choose Destination
Oncotarget. 2016 May 10;7(19):26926-34. doi: 10.18632/oncotarget.8731.

BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia.

Author information

1
Division of Oncology, Department of Medicine and Pathology, Stanford University, Stanford, CA, United States of America.

Abstract

Oncogene inactivation in both clinical targeted therapies and conditional transgenic mouse cancer models can induce significant tumor regression associated with the robust induction of apoptosis. Here we report that in MYC-, RAS-, and BCR-ABL-induced acute lymphoblastic leukemia (ALL), apoptosis upon oncogene inactivation is mediated by the same pro-apoptotic protein, BIM. The induction of BIMin the MYC- and RAS-driven leukemia is mediated by the downregulation of miR-17-92. Overexpression of miR-17-92 blocked the induction of apoptosis upon oncogene inactivation in the MYC and RAS-driven but not in the BCR-ABL-driven ALL leukemia. Hence, our results provide novel insight into the mechanism of apoptosis upon oncogene inactivation and suggest that induction of BIM-mediated apoptosis may be an important therapeutic approach for ALL.

KEYWORDS:

BIM; apoptosis; oncogene inactivation; targeted therapies

PMID:
27095570
PMCID:
PMC5053622
DOI:
10.18632/oncotarget.8731
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

The authors disclose no potential conflicts of interest.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center